// App-Quantinova.ai

e15743 : The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients.

Researchers

Presenter

  • Andrea Wang-Gillam

Principal Investigators

  • Marcus Smith Noel

  • Stefan Sleijfer

  • Heiyoun Jung

  • Lisa Lohr

  • Niky Zhao

  • Shichang Miao

  • Antonia Potarca

  • Israel Charo

  • Petrus Bekker

  • Thomas J. Schall

Medical Centers

  • Siteman Cancer Center, Washington University, Saint Louis, MO

  • Wilmot Cancer Institute, University of Rochester, Rochester, NY

  • Erasmus MC Cancer Institute, Department of Medical Oncology and Cancer Genomics Netherlands, Rotterdam, Netherlands

  • ChemoCentryx, Mountain View, CA

  • ChemoCentryx, Mountain View, CA

  • ChemoCentryx, Mountain View, CA

Locations

  • United States

  • Netherlands

Companies

  • ChemoCentryx, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • C-C Motif Chemokine Receptor 2

Drug/Treatment

  • FOLFIRINOX

  • CCX872-B

  • CCX872

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02345408

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved